Mega Lifesciences バランスシートの健全性
財務の健全性 基準チェック /66
Mega Lifesciences has a total shareholder equity of THB9.8B and total debt of THB176.7M, which brings its debt-to-equity ratio to 1.8%. Its total assets and total liabilities are THB15.0B and THB5.2B respectively. Mega Lifesciences's EBIT is THB3.0B making its interest coverage ratio -72.3. It has cash and short-term investments of THB3.7B.
主要情報
1.8%
負債資本比率
฿176.75m
負債
| インタレスト・カバレッジ・レシオ | -72.3x |
| 現金 | ฿3.69b |
| エクイティ | ฿9.79b |
| 負債合計 | ฿5.18b |
| 総資産 | ฿14.97b |
財務の健全性に関する最新情報
更新なし
Recent updates
財務状況分析
短期負債: MEGA's short term assets (THB10.7B) exceed its short term liabilities (THB4.8B).
長期負債: MEGA's short term assets (THB10.7B) exceed its long term liabilities (THB425.0M).
デット・ツー・エクイティの歴史と分析
負債レベル: MEGA has more cash than its total debt.
負債の削減: MEGA's debt to equity ratio has reduced from 21.1% to 1.8% over the past 5 years.
債務返済能力: MEGA's debt is well covered by operating cash flow (1509%).
インタレストカバレッジ: MEGA earns more interest than it pays, so coverage of interest payments is not a concern.